Key messages from the AGM:
- The results in Georgia, if repeated in a larger trial, would be good enough for marketing approval. If all else fails, NOX would still have a valuable fall-back opportunity.
- If radiated tumours disappear, but an abscopal response does not occur, this result would also justify a registration trial
- If an abscopal response can be achieved using low dose radiation plus NOX66, it would logically become the treatment of choice - for everyone.
Add to My Watchlist
What is My Watchlist?
